Treating psoriasis with etanercept in Italian clinical practice: Prescribing practices and duration of remission following discontinuation

Clinical Drug Investigation

Volumn 30, Issue 8, 2010, Pages 507-516

  Arcese, Annalisa ^a   Aste, Nicola ^b   Bettacchi, Alberta ^c   Camplone, Germana ^a   Cantoresi, Franca ^a   Caproni, Marzia ^d   Damico, Domenico ^e   Fabbri, Paolo ^d   Filosa, Giorgio ^f   Galluccio, Antonia ^g   Hansel, Katharina ^h   Lisi, Paolo ^h   Micali, Giuseppe ⁱ   Musumeci, Maria Letizia ⁱ   Nicolini, Massimiliano ^f   Parodi, Aurora ^j   Patania, Mario ^k   Pezza, Michele ^g   Potenza, Concetta ^a   Richetta, Antonio ^a   Simonacci, Marco ^c   Trevisan, Piergiusto ^k   Valenti, Giancarlo ^e   Calvieri, Stefano ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Macerata Hospital   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UO Dermatology of Catanzaro   (Italy)

^f Jesi Hospital   (Italy)

^g Department of Radiology   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ UNIVERSITY OF CATANIA   (Italy)

^j UNIVERSITY OF GENOA   (Italy)

^k UNIVERSITY OF TRIESTE   (Italy)

more..

Author keywords

Etanercept, therapeutic use; Psoriasis, treatment

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOL; SALICYLIC ACID; TAR; VITAMIN D DERIVATIVE; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BASAL CELL CARCINOMA; BODY SURFACE; CHILD; CLINICAL PRACTICE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE INFLAMMATION; ITALY; MAJOR CLINICAL STUDY; MALE; NOSE CARCINOMA; OBSERVATIONAL STUDY; PHOTOTHERAPY; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; REMISSION; RETREATMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; TOOTH ABSCESS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULTRAVIOLET B RADIATION; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME;

FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77954198236     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11537470-000000000-00000     Document Type: Article

References (19)

1. Meier M, Sheth PB. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol 2009; 38: 1-20
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5): 826-850 (Pubitemid 351509656)
3. Nast A, Kopp IB, Augustin M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5 Suppl. 3: 1-119
4. Barker J. Skin diseases with high public health impact: psoriasis. Eur J Dermatol 2007; 17 (6): 563-564
5. European Medicines Authority. Etanercept (Enbrel®): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Enbrel/H-262-PI-en.pdf [Accessed 2009 Mar 4]
6. Boehncke WH, Brasie RA, Barker J, et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006; 20 (8): 988-998
7. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349 (21): 2014-2022
8. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139 (12): 1627-32; discussion 1632
9. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152(6): 1304-1312
10. Leonardi CL, Elewski B, Carnisa C, et al. The efficacy and safety of etanercept in the retreatment of psoriasis after relapse [abstract P568]. J Acad Dermatol 2004; 50: 146
11. Tyring S, Rosoph L, Toth D, et al. A 2-year phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: results from the 3-month double-blind period [abstract no. P2700]. American Academy of Dermatology 2005; Feb 18-22, New Orleans (LA)
12. Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005; 6 (2): 121-136
13. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10 (46): 1-233, i-iv
14. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Der-matol 2005; 153 (6): 1192-1199
15. Bhosle MJ, Kulkarni A, Feldman SR, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35
16. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14 (4): 267-271
17. National Psoriasis Foundation. National Psoriasis Foundation 2008 Survey Panel Snapshot [online]. Available from URL: http://www.psoriasis.org/ NetCommunity/Document.Doc?id=193 [Accessed 2009 Jul 8]
18. Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006; 17 (1): 24-28
19. Lebwohl M. Psoriasis. Lancet 2003; 361 (9364): 1197-1204